🏛️ Verified NIH Record • Updated 2026-08-26

Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer (NCT05132075)

🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic Sponsor: Novartis Pharmaceuticals

🩺 Plain-English Summary (8th-Grade Level)

This is a phase III randomized open label study designed to compare JDQ443 as monotherapy to docetaxel in participants with advanced non-small cell lung cancer (NSCLC) harboring a KRAS G12C mutation who have been previously treated with a platinum-based chemotherapy and immune checkpoint inhibitor therapy either in sequence or in combination.

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (4 items) and avoid the listed exclusions (5 items).

Location: Valley Medical Center Research — Renton, Washington

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

Usually NOT eligible if any of the following apply:

  • Exclusion Criteria:
  • Participants who have previously received docetaxel (except if received in neoadjuvant or adjuvant setting with no progression within 12 months after the of end of treatment), or any other KRAS G12C inhibitor.
  • Participant has EGFR-sensitizing mutation and/or ALK rearrangement by local laboratory testing. Participants with other druggable alterations will be excluded if required by local guidelines.
  • Participant has known active central nervous system (CNS) metastases and/or carcinomatous meningitis
  • Participant has an history of interstitial lung disease or pneumonitis grade \> 1. Other inclusion/exclusion criteria may apply

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (51 Sites)

  • Valley Medical Center Research — Renton, Washington
  • Novartis Investigative Site — CABA, Buenos Aires
  • Novartis Investigative Site — Pilar, Buenos Aires
  • Novartis Investigative Site — Auchenflower, Queensland
  • Novartis Investigative Site — South Brisbane, Queensland
  • Novartis Investigative Site — Montreal, Quebec
  • Novartis Investigative Site — Sherbrooke, Quebec
  • Novartis Investigative Site — Fuzhou, Fujian
  • Novartis Investigative Site — Guangzhou, Guangdong
  • Novartis Investigative Site — Harbin, Heilongjiang
  • Novartis Investigative Site — Changsha, Hunan
  • Novartis Investigative Site — Shengyang, Liaoning
  • Novartis Investigative Site — Jinan, Shandong
  • Novartis Investigative Site — Hangzhou, Zhejiang
  • Novartis Investigative Site — Beijing,
  • Novartis Investigative Site — Turku,
  • Novartis Investigative Site — Athens, GR
  • Novartis Investigative Site — Athens,
  • Novartis Investigative Site — Heraklion Crete.,
  • Novartis Investigative Site — Hong Kong,
  • Novartis Investigative Site — Kowloon,
  • Novartis Investigative Site — Budapest,
  • Novartis Investigative Site — Reykjavik,
  • Novartis Investigative Site — Jaipur, Rajasthan
  • Novartis Investigative Site — Delhi,

💰 Cost, Insurance & Patient Rights

  • 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
  • Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
  • Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
🏛️ View Official NIH Record ↗